Caladrius Biosciences Receives Orphan Drug Designation for CLBS03 to Treat Type 1 Diabetes
BASKING RIDGE, N.J., May 12, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider (“PCT”) with a select …